Loading organizations...
Euclises Pharmaceuticals is a technology company.
Euclises Pharmaceuticals develops novel oral, small-molecule drugs for advanced oncology treatments. Its core approach creates third-generation cyclooxygenase-2 (COX-2) inhibitors, designed for improved safety and efficacy across cancer indications. By targeting proven cancer biology, Euclises expands immuno-oncology therapies, facilitating combination with other treatments and addressing unmet needs in care.
Founded in 2011, Euclises originated from Dr. John Talley, distinguished inventor of drugs including Celebrex. He partnered with Randall Weiss, Ph.D., MBA, recognized for pharmaceutical management, and Robert Karr, M.D. Their insight identified a need for safer, more effective COX-2 inhibitors in oncology, leveraging Dr. Talley's discoveries to establish the company.
The company's pipeline targets cancer patients, aiming to improve therapeutic outcomes and quality of life. Euclises envisions potent, well-tolerated small-molecule therapies offering treatment options. Its mission is to advance cancer care by delivering innovative, accessible treatments, striving for greater hope and better prognoses for individuals battling disease.
Euclises Pharmaceuticals has raised $6.3M across 4 funding rounds.
Euclises Pharmaceuticals has raised $6.3M in total across 4 funding rounds.
Euclises Pharmaceuticals, Inc. is a biotechnology startup developing novel COX-2 inhibitors under its proprietary Euclicoxib platform to treat cancers like lung, colorectal, and pancreatic, as well as pain and inflammation.[1][2][3][4][5] Based in St. Louis, MO, the company serves oncology patients by addressing limitations of earlier COX-2 drugs like Celebrex, improving safety, efficacy, and patient selection via validated biomarkers to disrupt the tumor microenvironment and enhance immuno-oncology therapies.[1][4][5] With ~4 employees, it raised ~$5.4M in funding (including a $1.3M Series A in 2014) and remains in the product development stage, currently advancing ECP-1014 for pain (pending clinical phase) from its BioGenerator accelerator base.[1][2][3][4][5]
Founded in October 2011, Euclises emerged from the expertise of John Talley, its co-founder and CSO, who invented Celebrex and holds over 200 U.S. patents from roles at G.D. Searle and Ironwood Pharmaceuticals.[1] Randall Weiss serves as co-founder, while Rajesh Devraj, President & CEO, brings 18+ years from Pfizer, Jubilant Biosys, and Deciphera, having advanced eight candidates to clinical trials.[1] The idea stemmed from clinical validation of COX-2's role in cancer—underserved by older inhibitors—leading to novel Euclicoxibs optimized for oncology, with early traction via St. Louis Arch Angels and Cultivation Capital funding in 2014.[1][2]
Euclises rides the immuno-oncology wave, targeting COX-2—a clinically proven but underexploited cancer driver—amid rising demand for precision therapies in hard-to-treat solid tumors like pancreatic and lung cancers.[1][4][5] Timing aligns with post-2020 advances in biomarker-guided treatments and combination regimens, fueled by market forces like immunotherapy expansion (e.g., checkpoint inhibitors) and Big Pharma's oncology push.[4] In St. Louis's biotech hub (via BioGenerator/CORTEX), it bolsters the local ecosystem by validating academic-industry translation, attracting early VC like Cultivation Capital, and pioneering safer COX-2 reactivation post-Celebrex cardiovascular concerns.[1][2][3]
Euclises is poised to nominate a lead clinical candidate from its Euclicoxib portfolio, potentially entering trials for oncology indications by 2026-2027, building on ECP-1014 momentum and team expertise.[2][5] Trends like AI-driven drug design, combo immuno-therapies, and COX-2 biomarker refinement will accelerate progress, though funding and trial recruitment remain hurdles for small biotechs. Its influence could grow by licensing to majors or partnering in St. Louis's ecosystem, transforming validated science into viable cancer treatments—echoing Talley's Celebrex legacy with safer, oncology-optimized inhibitors.[1][4]
Euclises Pharmaceuticals has raised $6.3M in total across 4 funding rounds.
Euclises Pharmaceuticals's investors include GE Ventures, iSelect Fund, Techstars, BioGenerator, Cultivation Capital, St. Louis Arch Angels, Rick Ryan, ABC Laboratories, Charlie Bolten, Missouri Technology Corporation, Robert Calcaterra, St. Louis County Port Authority.
Euclises Pharmaceuticals has raised $6.3M across 4 funding rounds. Most recently, it raised $1.0M Venture Round in November 2016.
| Date | Round | Lead Investors | Other Investors |
|---|---|---|---|
| Nov 1, 2016 | $1.0M Venture Round | GE Ventures, iSelect Fund, Techstars | |
| Sep 1, 2015 | $2.0M Venture Round | GE Ventures, iSelect Fund, Techstars | |
| Apr 7, 2015 | $2.0M Series A Extension | BioGenerator, Cultivation Capital, St. Louis Arch Angels | |
| Sep 9, 2014 | $1.3M Series A | Rick Ryan | ABC Laboratories, Charlie Bolten, Missouri Technology Corporation, Robert Calcaterra, St. Louis County Port Authority |